drugset / Trial / NCT05619861
CAR-T Cells in the Treatment of Malignant Hematological Tumors
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of autologous CAR-T cell injection in the treatment of recurrent and refractory hematopoietic and lymphoid tissue tumors
Timeline
- Start
- 2020-04-27
- Primary completion
- 2023-01-26
- Completion
- 2023-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T | Cell therapy | — | Intravenous |